EHA 2023 | The toxicity of induction therapy in AML
Pinkal Desai, MD, MPH, Weill Cornell Medical College, New York City, NY, comments on the toxicity associated with induction regimens in acute myeloid leukemia (AML). She explains that intense chemotherapy treatments can be highly toxic and are mainly used for young and fit patients. On the other hand, less intense regimens with better tolerability are given to older and less fit individuals. Now, the question is whether these more manageable treatments can also be given to young and fit patients while achieving the same desired outcomes. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS, Servier, Janssen Research
